Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Authors:
- Meletios DimopoulosMDMeletios Dimopoulos
- Katja WeiselKWKatja Weisel
- Niels W.C.J. van de DonkNDNiels W.C.J. van de Donk
- Karthik RamasamyKRKarthik Ramasamy
- Barbara GamberiBGBarbara Gamberi
- Matthew StreetlyMSMatthew Streetly
- Massimo OffidaniMassimo Offidani
- Frank BridouxFBFrank Bridoux
- Javier de la RubiaJRJavier de la Rubia
- Maria-Victoria MateosMMMaria-Victoria Mateos
- Antonio ArdizzoiaAAAntonio Ardizzoia
- Elisabeth KueenburgEKElisabeth Kueenburg
- 10 July 2018
- journal article
- conference paper
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (20) , 2035-2043
Abstract
Purpose: Renal impairment (RI) limits treatment options in patients with relapsed/refractory multiple myeloma (RRMM). Here, we prospectively studied pomalidomide plus low-dose dexamethasone (LoDEX) in patients with RRMM and moderate or severe RI, including those receiving hemodialysis. Patients and Methods: MM-013, a noncomparative, European phase II trial, enrolled three patient cohorts: moderate RI (cohort A; estimated glomerular filtration rate, 30 to < 45 mL/min/1.73 m2); severe RI (cohort B; estimated glomerular filtration rate, < 30 mL/min/1.73 m2); and severe RI that requires hemodialysis (cohort C). Patients received pomalidomide 4 mg/d on days 1 to 21 and LoDEX 20 or 40 mg once per week in 28-day cycles. The primary end point was overall response rate. Results: Of 81 enrolled patients (33, 34, and 14 patients in cohorts A, B, and C, respectively), 13 were still receiving treatment at data cutoff (January 28, 2017). Overall response rates were 39.4%, 32.4%, and 14.3%, with a median duration of response of 14.7 months, 4.6 months, and not estimable, respectively. Of importance, 100%, 79.4%, and 78.6% of patients, respectively, achieved disease control. With a median follow-up of 8.6 months, median overall survival was 16.4 months, 11.8 months, and 5.2 months, respectively. Complete renal responses were observed only in cohort A (18.2%), and no patients in cohort C became hemodialysis independent. Grade 3 and 4 hematologic treatment-emergent adverse events and pomalidomide discontinuations as a result of treatment-emergent adverse events occurred more frequently in cohort C. Pomalidomide pharmacokinetics were comparable among the three renal cohorts. Conclusion: Pomalidomide 4 mg/d plus LoDEX is efficacious in patients with RRMM with moderate or severe RI, including those who had more advanced disease and required hemodialysis. The safety profile was acceptable among the three groups, and no new safety signals were observed.Keywords
This publication has 27 references indexed in Scilit:
- Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal ImpairmentClinical Cancer Research, 2012
- Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjectsCancer Chemotherapy and Pharmacology, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working GroupJournal of Clinical Oncology, 2010
- Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II StudyJournal of Clinical Oncology, 2010
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- Renal, hematologic and infectious complications in multiple myelomaBest Practice & Research Clinical Haematology, 2005
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Renal failure in multiple myeloma: reversibility and impact on the prognosisEuropean Journal of Haematology, 2000
- Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myelomaBlood Reviews, 1999